Axsome Therapeutics is on a tear this year – with shares skyrocketing over 3,000%. This comes as the biotech company’s migraine drug posted successful results in a late-stage study. Yahoo Finance’s Anjalee Khemlani joins Seana Smith on The Ticker to discuss. …read more
Source:: Yahoo Finance
